The first week in Elon Musk and Sam Altman's federal civil trial has wrapped. BI's Katherine Li shares what week one was like.

The Musk-Altman legal battle is in its second week, with OpenAI cofounder Greg Brockman expected to spend 3 hours on the stand next week. Altman and Musk both appeared in court, underscoring the high stakes and public interest in the case. The article is mostly courtroom color and trial logistics rather than new substantive developments, so near-term market impact appears limited.

Analysis

This trial is less about near-term fundamentals for AI and more about optionality around control, credibility, and talent retention. The market overweights headline risk, but the real second-order effect is that a prolonged public airing of internal disputes can harden enterprise buyers' preference for vendors with cleaner governance and less founder volatility, which modestly benefits the broader incumbent cloud/AI ecosystem rather than any one name. If the testimony reinforces a narrative of fractured AI governance, the discount rate on long-dated frontier-AI cash flows rises: investors will demand more proof of execution, not just vision.

The biggest tactical implication is for sentiment around management quality in high-multiple software/AI adjacencies. A messy trial can catalyze rotation away from story stocks where valuation depends on trust in a small set of key operators and toward platform businesses with diversified decision-making and larger balance sheets. That matters most over the next 2-8 weeks if the courtroom coverage keeps surfacing internal documents, because these cases tend to move from curiosity to regime change only when a compelling chronology emerges.

The contrarian view is that the market may be underestimating how little this changes the operating trajectory of the AI stack. In a sector where capex, compute access, and distribution partnerships matter more than personality conflicts, litigation noise is usually transient unless it triggers employee churn, customer defection, or a financing event. Absent evidence of those three, the tradeable impact should fade after each testimony cycle, creating opportunities to fade headline-driven dislocations rather than bet on a durable re-rating.

Key Decisions for Investors

• Fade any strength in high-multiple AI sentiment baskets on trial headlines: short SMH or a basket of unprofitable AI software names for 2-4 weeks, using a tight stop if the case produces no new damaging evidence.
• Relative value: long MSFT / short a basket of governance-sensitive AI story stocks (e.g., RBLX, C3AI, AI) over the next month; thesis is that enterprise buyers reward stability and platform scale when governance risk is in the spotlight.
• If you want direct litigation optionality, buy short-dated downside put spreads on AI-adjacent speculative names into key witness days; risk/reward is attractive because volatility is event-driven, but premium decay is rapid if testimony is uneventful.
• For a cleaner expression, pair long GOOGL against short ARKK for 4-6 weeks: the former benefits if the market treats AI as a capital-intensive platform war, while the latter is vulnerable to multiple compression when founder risk becomes a theme.
• Do not chase broad AI beta until after the Brockman testimony window; if the record confirms internal discord without operational fallout, the appropriate trade is to cover shorts into the weakness rather than press them.